Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China Pharma Holdings (CPHI) Non-Current Debt (2016 - 2025)

China Pharma Holdings' Non-Current Debt history spans 12 years, with the latest figure at $1.3 million for Q2 2025.

  • For Q2 2025, Non-Current Debt fell 5.93% year-over-year to $1.3 million; the TTM value through Jun 2025 reached $1.3 million, down 5.93%, while the annual FY2024 figure was $1.4 million, 1.47% down from the prior year.
  • Non-Current Debt reached $1.3 million in Q2 2025 per CPHI's latest filing, down from $1.4 million in the prior quarter.
  • In the past five years, Non-Current Debt ranged from a high of $1.5 million in Q3 2022 to a low of $325072.0 in Q2 2021.
  • Average Non-Current Debt over 5 years is $1.2 million, with a median of $1.4 million recorded in 2023.
  • Peak YoY movement for Non-Current Debt: tumbled 83.56% in 2021, then surged 92.5% in 2022.
  • A 5-year view of Non-Current Debt shows it stood at $800000.0 in 2021, then soared by 92.5% to $1.5 million in 2022, then decreased by 8.32% to $1.4 million in 2023, then dropped by 1.47% to $1.4 million in 2024, then dropped by 5.12% to $1.3 million in 2025.
  • Per Business Quant, the three most recent readings for CPHI's Non-Current Debt are $1.3 million (Q2 2025), $1.4 million (Q1 2025), and $1.4 million (Q4 2024).